摘要
原发性中枢神经系统淋巴瘤（PCNSL）是一种较罕见的中枢神经系统恶性肿瘤，其生物学行为具有侵袭性，临床无典型性，病理形态存在异质性，影像表现多样性，依靠病理免疫组织化学及分子生物学方可确诊。各种以大剂量甲氨蝶呤为基础的治疗方案，改善了PCNSL的治疗效果，并成为PCNSL的标准治疗措施，患者的生存率较单用放疗得以显著地提高。早期诊断并进行有效的综合治疗是延长PCNSL患者生存期和改善生活质量的关键。
Primary central nervous system lymphoma （PCNSL） is a rare form of non-Hodgkin lympho- ma （NHL） and has aggressive biological behavior. Due to absence of typical clinical presentation, heteroge-neity of pathological morphology and multiple neuroimaging appearance and so on, the immunohistochemistry and molecular biology are of vital importance in accurate diagnosis of PCNSL. The development of regimen based on high-dose MTX leads to significant changes in the PCNSL treatment and it has become a generally recognized regimen. Compared with single radiotherapy, the survival rate has evidently been raised. Early diag- nosis and surgical removal of the tumors combined with effective radiotherapy and chemotherapy are the key to extending survival period and improving living quality of patients with PCNSL.
出处
《国际肿瘤学杂志》
CAS
2013年第8期621-624,共4页
Journal of International Oncology
关键词
中枢神经系统肿瘤
淋巴瘤
诊断
治疗
Central nervous system neoplasms
Lymphoma
Diagnosis
Therapy
